Detection of mutant Huntingtin aggregation conformers and modulation of SDS-soluble fibrillar oligomers by small molecules

Journal of Huntington's Disease

Volumn 1, Issue 1, 2012, Pages 119-132

  Sontag, Emily Mitchell ^a   Lotz, Gregor P ^b,c,f   Yang, Guocheng ^b,c   Sontag, Christopher J ^a,d   Cummings, Brian J ^a,d   Glabe, Charles G ^d   Muchowski, Paul J ^b,c,e   Thompson, Leslie Michels ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

amyloid fibrils; CEP 1347; epigallocatechin 3 gallate; Huntingtin protein; Huntington's disease; Time Lapsed Imaging

Indexed keywords

AMYLOID; HTT PROTEIN, HUMAN; NERVE PROTEIN;

ANIMAL; BIOLOGICAL MODEL; BRAIN CHEMISTRY; CHEMISTRY; GENETICS; HUMAN; HUNTINGTON CHOREA; MOUSE; MUTATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

AMYLOID; ANIMALS; BRAIN CHEMISTRY; CELL LINE, TUMOR; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MUTATION; NERVE TISSUE PROTEINS;

EID: 84874280591     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-2012-129004     Document Type: Article

References (41)

1. Gusella JF, MacDonald ME. Huntington's disease. Semin Cell Biol. 1995;6(1):21-8.
2. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 1997;90(3):549-58.
3. Morley JF, Brignull HR, Weyers JJ, Morimoto RI. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2002;99(16):10417-22. Epub 2002/07/18.
4. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537-48.
5. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277(5334):1990-3.
6. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805-10.
7. Glabe CG. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem Sci. 2004;29(10):542-7.
8. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300(5618):486-9.
9. Poirier MA, Li H, Macosko J, Cai S, Amzel M, Ross CA. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem. 2002;277(43):41032-7. Epub 2002/08/13.
10. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2(1):18.
11. Sathasivam K, Lane A, Legleiter J, Warley A, Woodman B, Finkbeiner S, et al. Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Hum Mol Genet. 2010;19(1):65-78. Epub 2009/10/15.
12. Wu JW, Breydo L, Isas JM, Lee J, Kuznetsov YG, Langen R, et al. Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. J Biol Chem. 2010;285(9):6071-9. Epub 2009/12/19.
13. Baglioni S, Casamenti F, Bucciantini M, Luheshi LM, Taddei N, Chiti F, et al. Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci. 2006;26(31):8160-7. Epub 2006/08/04.
14. Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chemistry & Biology. 1997;4(2):119-25. Epub 1997/02/01.
15. Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem. 2007;282(14):10311-24.
16. Lasagna-Reeves CA, Glabe CG, Kayed R. Amyloid-beta annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem. 2011;286(25):22122-30. Epub 2011/04/22.
17. Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis. 2009;35(3):352-8. Epub 2009/06/16.
18. Kayed R, Glabe CG. Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol. 2006;413:326-44.
19. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nature Reviews Neuroscience. 2010;11(3):155-9. Epub 2009/12/24.
20. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2010;11(4):301-7. Epub 2010/03/24.
21. Lotz GP, Legleiter J, Aron R, Mitchell EJ, Huang SY, Ng C, et al. Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J Biol Chem. 2010;285(49):38183-93. Epub 2010/09/25.
22. Wacker JL, Zareie MH, Fong H, Sarikaya M, Muchowski PJ. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol. 2004;11(12):1215-22. Epub 2004/11/16.
23. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A. 2000;97(14):7841-6. Epub 2000/06/22.
24. Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, Regulier E, et al. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J Neurochem. 2008;104(3):846-58.
25. Legleiter J, Mitchell E, Lotz GP, Sapp E, Ng C, DiFiglia M, et al. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem. 2010;285(19):14777-90. Epub 2010/03/12.
26. Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nature chemical biology 2011;7(12):925-34. Epub 2011/11/01.
27. Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L, et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci USA. 2003;100(10): 5950-5.
28. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493-506.
29. Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW, et al. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc Natl Acad Sci U S A. 2005;102(10):3777-81.
30. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, et al. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet. 2006;15(2):273-85.
31. Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A. 2005;102(3):892-7.
32. Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, et al. Green tea (-)-epigallocatechingallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. 10.1093/hmg/ddl210. Hum Mol Genet 2006:ddl210.
33. Maroney AC, Glicksman MA, Basma AN, Walton KM, Knight E Jr, Murphy CA, et al. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci. 1998;18(1):104-11. Epub 1998/01/24.
34. Roux PP, Dorval G, Boudreau M, Angers-Loustau A, Morris SJ, Makkerh J, et al. K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK. J Biol Chem. 2002;277(51):49473-80. Epub 2002/10/22.
35. Xu Z, Maroney AC, Dobrzanski P, Kukekov NV, Greene LA. The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Molecular and Cellular Biology. 2001;21(14):4713-24. Epub 2001/06/21.
36. Wang LH, Besirli CG, Johnson EM Jr. Mixed-lineage kinases: A target for the prevention of neurodegeneration. Annual review of pharmacology and toxicology. 2004;44:451-74. Epub 2004/01/28.
37. Apostol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci. 2008.
38. Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, et al. A small-molecule therapeutic lead for Huntington's disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci U S A. 2007;104(42):16685-9. Epub 2007/10/11.
39. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008;15(6):558-66.
40. Rich T, Assier E, Skepper J, Segard HB, Allen RL, Charron D, et al. Disassembly of nuclear inclusions in the dividing cell-a novel insight into neurodegeneration. Hum Mol Genet. 1999;8(13):2451-9. Epub 1999/11/11.
41. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends in Cell Biology. 2000;10(12):524-30. Epub 2000/12/21.